Penetrium Bioscience Inc
187660
Company Profile
Business description
Penetrium Bioscience Inc is engaged in CRO services and develops anticancer drugs that utilize proprietary Drug Delivery System (DDS) technology to enhance the bioavailability of active pharmaceutical ingredients (APIs) and improve selectivity for target tumor sites.
Contact
166, Magokdong-ro
Room 603
Gangseo-gu
Seoul07790
KORT: +82 27301457
Sector
Healthcare
Stock type
Defensive
Industry
Medical Care Facilities
Fiscal Year End
31 December 2026
Employees
147
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.40 | 19.00 | -0.21% |
| CAC 40 | 8,157.82 | 69.50 | -0.84% |
| DAX 40 | 24,128.98 | 26.47 | -0.11% |
| Dow JONES (US) | 49,171.54 | 138.78 | -0.28% |
| FTSE 100 | 10,379.08 | 77.93 | -0.75% |
| HKSE | 25,978.07 | 62.87 | 0.24% |
| NASDAQ | 24,806.45 | 367.95 | 1.51% |
| Nikkei 225 | 59,716.18 | 575.95 | 0.97% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,156.92 | 48.52 | 0.68% |
| S&P/ASX 200 | 8,786.50 | 12.10 | -0.14% |
| SSE Composite Index | 4,079.90 | 13.35 | -0.33% |